利奈唑胺治疗ICU革兰阳性球菌感染的疗效及安全性观察

为了评估利奈唑胺治疗ICU革兰阳性球菌感染的疗效与安全性，回顾性分析了我院中心ICU接受利奈唑胺治疗的28例革兰阳性球菌感染患者的临床资料。结果显示治疗的总有效率为75％（21／28），耐甲氧西林金黄色葡萄球菌感染患者有效率73．33％（11／15），表皮葡萄球菌感染患者有效率66．67％（4／6），屎肠球菌感染患者有效率80％（4／5），溶血葡萄球菌感染患者有效率100％（2／2），人葡萄球菌感染患者有效率100％（2／2）。治疗过程中不良反应发生率为25％。不良反应经对症处理后好转，无需停药。故得出结论，利奈唑胺是治疗革兰阳性球菌感染有效、安全的药物，值得进一步临床验证。

Efficacy and Safety of Linezolid in the Treatment of Gram--positive Cocci Infections in ICU

To evaluate the efficacy and safety of Linezolid in the treatment of gram--positive Cocci infections in ICU, A retrospective analysis of the clinical data was conducted for 28 patients with Gram--positive Cocci infections and treated with Linezolid in center intensive care unit （ICU）. The results showed the total efficacy rate was 75% （21/28）, 73.33 % （11/15） among the patients with the infection of Meticillin--resistant Staphylococcus aureus （MRSA）, 66.67% （4/6）among the patients with the infection of Staphylococcus epidermidis, 80% （ 4/5 ） among the patients with the infection of Enterococcus faecium, 100% （ 2/2 } among the patients with the infection of Staphylococcus haemolyticus, 100 % （ 2/2 ） among the patients with the infection of Staphylococcus hominis, the drug--related side effect rate was 25 %. Therefore, Linezolid is likely to be an effective and safe treatment for Gram--positive cocci infections in ICU patients,and warrant further clinical study.